Could an existing blood test improve treatment choices – and outcomes – in colon cancer?

An EHR-derived phenotypic disease catalog allows replication of decades of work on HLAs

Eleftherios P. Diamandis, Hold ’em for Life Chair in Prostate Cancer Biomarkers, University of Toronto.

Two experts explain why they believe ctDNA analysis is the future of cancer pathology

George Calin, Professor, Department of Experimental Therapeutics, and Co-Director, The Center for RNA Interference and Non-coding RNAs, MD Anderson Cancer Center, USA

A 30-year-old medical puzzle leads researchers to develop a new molecular therapy

New ctDNA assays could make more metastatic melanoma cases detectable

Using left-handed DNA to better monitor and control PCR

New software for analyzing genetic data could bring simple antibiotic resistance information to your tablet or laptop

As more and more emerging study data fails to definitively support cancer screening, is it time for a study design overhaul?